After that, mice were given 5% (w/v) DSS-containing drinking water for 7 d to trigger a colitis colon. Significant weight decrease, severe hematochezia, and intestinal epithelium structure loss of mice following DSS induction were observed (Fig.
S28), indicating the successful establishment of mice IBD. Direct pH measurement of intestinal tissues showed pH values greater than 7 even after 7 d of DSS induction (Fig.
S29), guaranteeing a suitable working environment for DHKNase
-6 to neutralize ROS. Subsequently, mice were treated with PBS, catechin, and DHKNase
-6 on the predetermined days, with the collection of colon samples 2 d after the final treatment (Fig.
5B). Catechin, a widely studied natural substance for the effective treatment of IBD and showing no bifacial enzyme ability as depicted in Fig.
2A, was employed to provide a therapeutic contrast. After 9 d of therapy, DHKNase-
6 predominantly interfered with weight loss, colon length shortness, and colon damage index increase, while the other formulations exhibited less anti-IBD outcomes. In addition, it was observed that the multi-dose administration of DHKNase
-6 did not cause the accumulation of acidic groups in the colon microenvironment to impair the ROS scavenging function of DHKNase
-6 (Fig.
S30). As depicted in Fig.
5C, during the first 2 d of treatment, all mice except those in the PBS group showed a sustained weight loss, while those in the DSS group declined to 89.5%. After 2 d of remedy, mice treated with DHKNase-
6 began to regain weight. On the fourth day, the mice's body weight in the DHKNase-
6 (5×) group recovered to reach 101.2%, while the body mass of mice within the DSS cohort still continued to decrease to 87%. After 9 d of treatment, colon length in the DSS group still presented a severe reduction to 6.35 cm on average, whereas it was recovered to 8.2 cm on average after DHKNase-
6 (5×) cure (Fig.
5D and E), demonstrating the significant therapy efficacy of DHKNase-
6 for IBD. There was observed intact colonic epithelial structure of regular finger-shaped crypt and goblet cells after DHKNase-
6 (5×) therapy, while the colon in the other treatment groups still showed pathological symptoms such as epithelial structure loss and ulceration (Fig.
5F). The similar colonic damage score compared with the PBS group further indicated the recovery of the colon from a pathological to a physiological state after DHKNase-
6 therapy (Fig.
5G). The IBD-related myeloperoxidase (MPO) and SOD activity had been studied to have a significant rise and were down-regulated by DHKNase-
6 (Fig.
5H and Fig.
S31A). On the contrary, the CAT enzyme, which helps the host to clear the excessive accumulation of ROS in the intestine, was up-regulated by DHKNase-
6 treatment (Fig.
S31B), demonstrating that DHKNase-
6 significantly increased the antioxidant and ROS scavenging capacity of the intestine in IBD mice. Additionally, ELISA analysis also confirmed that DHKNase-
6 could enhance the levels of growth factors TGF-β1, VEGF, and inflammation-deterrent cytokine IL-10, but decreased the inflammation-propulsive factors expression of IL-1β, IL-6, as well as the TNF-α (Fig.
5I to L and Fig.
S32), facilitating the intestinal tissue and blood vessel regeneration and inhibition of inflammation. Beyond that, tail vein injection of high doses of DHKNase-
6 (300 mg kg
−1) presented no overt toxicodynamics to the major organs of mice, proving the possibility of systemic administration for DHKNase-
6 (Fig.
S33). Collectively, DHKNase-
6 showed superior efficacy for colitis therapy attributing to the enhanced ROS clearance, tissue regeneration, and inflammation suppression.